Compare
Catheter Precision, Inc. vs Sintx Technologies, Inc. vs Co-Diagnostics, Inc. vs RenovoRx, Inc.
| Latest fiscal year | Catheter Precision, Inc. VTAK | Sintx Technologies, Inc. SINT | Co-Diagnostics, Inc. CODX | RenovoRx, Inc. RNXT |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $819.0K | $1.02M | $622.5K | $1.12M |
| Revenue growth (YoY) | +95.0% | -64.7% | -84.1% | n/m |
| Gross margin | 92.3% | 45.3% | 64.3% | 70.9% |
| Operating margin | n/m | n/m | n/m | n/m |
| Net margin | n/m | n/m | n/m | -994.5% |
| Net income | -$17.18M | -$10.36M | -$46.90M | -$11.17M |
| EPS (Diluted) | n/a | -$6.16 | -$35.25 | -$0.32 |
| Operating cash flow | -$8.30M | -$8.57M | -$29.14M | -$10.97M |
| Free cash flow | -$8.31M | -$8.76M | -$29.84M | -$10.97M |
| Cash & equivalents | $88.0K | $4.14M | $11.88M | $7.02M |
| Total assets | $15.86M | $9.51M | $24.74M | $8.10M |
| Total liabilities | $9.21M | $6.58M | $4.11M | $2.67M |
| Shareholders' equity | $7.05M | $2.93M | $20.63M | $5.42M |
| Return on year-end equity | -243.6% | -353.8% | -227.3% | -206.0% |
| Shares outstanding | 1.74M | 3.97M | 2.10M | 36.61M |
Revenue, most recent five fiscal years
| Fiscal year | Catheter Precision, Inc. | Sintx Technologies, Inc. | Co-Diagnostics, Inc. | RenovoRx, Inc. |
|---|---|---|---|---|
| Latest | $819.0K Ended 2025-12-31 | $1.02M Ended 2025-12-31 | $622.5K Ended 2025-12-31 | $1.12M Ended 2025-12-31 |
| 1 year earlier | $420.0K Ended 2024-12-31 | $2.89M Ended 2024-12-31 | $3.92M Ended 2024-12-31 | $43.0K Ended 2024-12-31 |
| 2 years earlier | $442.0K Ended 2023-12-31 | $2.63M Ended 2023-12-31 | $6.81M Ended 2023-12-31 | n/a |
| 3 years earlier | $14.0K Ended 2022-12-31 | $1.56M Ended 2022-12-31 | $34.22M Ended 2022-12-31 | n/a |
| 4 years earlier | $22.0K Ended 2021-12-31 | $606.0K Ended 2021-12-31 | $97.89M Ended 2021-12-31 | n/a |